{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:38:47Z","timestamp":1759451927054,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T00:00:00Z","timestamp":1531872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"PhRMA Foundation Pre-Doctoral Fellowship"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.vaccine.2018.06.059","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T21:01:56Z","timestamp":1532034116000},"page":"6237-6247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Determining the optimal strategy for the live-attenuated herpes zoster vaccine in adults"],"prefix":"10.1016","volume":"36","author":[{"given":"M.J.","family":"Harvey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.T.","family":"Denton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.A.","family":"Prosser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.W.","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2018.06.059_b0005","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0304-3959(96)03122-3","article-title":"Pain and its persistence in herpes zoster","volume":"67","author":"Dworkin","year":"1996","journal-title":"Pain"},{"key":"10.1016\/j.vaccine.2018.06.059_b0010","first-page":"787","article-title":"Health care utilization and cost burden of herpes zoster in a community population","volume":"vol. 84","author":"Yawn","year":"2009"},{"key":"10.1016\/j.vaccine.2018.06.059_b0040","unstructured":"P. Rohan, Zoster Vaccine Live (oka\/merck) Zostavax, Report. Food and Drug Administration; 2005."},{"key":"10.1016\/j.vaccine.2018.06.059_b0045","doi-asserted-by":"crossref","unstructured":"Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012;cis638.","DOI":"10.1093\/cid\/cis638"},{"issue":"7","key":"10.1016\/j.vaccine.2018.06.059_b0050","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"and tolerability of herpes zoster vaccine in persons aged 50\u201359\u202fyears","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2018.06.059_b0055","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.06.059_b0060","doi-asserted-by":"crossref","unstructured":"Tseng HF, Luo Y, Hales Craig M, Harpaz Rafael, Sy Lina S, Bialek Stephanie R, et al. Declining herpes zoster vaccine effectiveness in adults 60 years and older. ID Week 2015; 2015.","DOI":"10.1093\/ofid\/ofv133.1476"},{"issue":"5","key":"10.1016\/j.vaccine.2018.06.059_b0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/0003-4819-145-5-200609050-00004","article-title":"Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"145","author":"Hornberger","year":"2006","journal-title":"Ann Internal Med"},{"issue":"49","key":"10.1016\/j.vaccine.2018.06.059_b0020","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.1016\/j.vaccine.2007.09.066","article-title":"Evaluation of the cost-effectiveness in the united states of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"25","author":"Pellissier","year":"2007","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2018.06.059_b0025","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1086\/514342","article-title":"Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"44","author":"Rothberg","year":"2007","journal-title":"Clinical Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2018.06.059_b0030","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7326\/M15-0093","article-title":"Cost-effectiveness of herpes zoster vaccine for persons aged 50 years","volume":"163","author":"Le","year":"2015","journal-title":"Ann Internal Med"},{"issue":"4","key":"10.1016\/j.vaccine.2018.06.059_b0035","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1177\/0272989X09353194","article-title":"Markov decision processes: a tool for sequential decision making under uncertainty","volume":"30","author":"Alagoz","year":"2010","journal-title":"Med Dec Mak"},{"key":"10.1016\/j.vaccine.2018.06.059_b0065","unstructured":"Puterman ML. Markov decision processes: discrete stochastic dynamic programming, Wiley series in probability and statistics. Wiley-Interscience; 2005 <https:\/\/books.google.com\/books?id=Y-gmAQAAIAAJ>, ISBN 9780471727828."},{"key":"10.1016\/j.vaccine.2018.06.059_b0070","doi-asserted-by":"crossref","unstructured":"Bellman Richard. A markovian decision process, Technical report. DTIC Document; 1957.","DOI":"10.1512\/iumj.1957.6.56038"},{"year":"1960","series-title":"Dynamic programming and markov processes, technology press research monographs","author":"Howard","key":"10.1016\/j.vaccine.2018.06.059_b0075"},{"key":"10.1016\/j.vaccine.2018.06.059_b0080","series-title":"Operations research and health care","first-page":"593","article-title":"Modeling medical treatment using markov decision processes","author":"Schaefer","year":"2004"},{"issue":"5","key":"10.1016\/j.vaccine.2018.06.059_b0085","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1287\/opre.1110.1019","article-title":"Or forum-a POMDP approach to personalize mammography screening decisions","volume":"60","author":"Ayer","year":"2012","journal-title":"Oper Res"},{"issue":"1","key":"10.1016\/j.vaccine.2018.06.059_b0090","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1287\/opre.1070.0480","article-title":"The optimal time to initiate HIV therapy under ordered health states","volume":"56","author":"Shechter","year":"2008","journal-title":"Oper Res"},{"issue":"10","key":"10.1016\/j.vaccine.2018.06.059_b0095","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1287\/mnsc.1040.0287","article-title":"The optimal timing of living-donor liver transplantation","volume":"50","author":"Alagoz","year":"2004","journal-title":"Manage Sci"},{"issue":"2","key":"10.1016\/j.vaccine.2018.06.059_b0100","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.artmed.2009.07.003","article-title":"Markov decision process applied to the control of hospital elective admissions","volume":"47","author":"Nunes","year":"2009","journal-title":"Artif Intell Med"},{"issue":"3","key":"10.1016\/j.vaccine.2018.06.059_b0105","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S1386-5056(00)00099-X","article-title":"Deciding when to intervene: a markov decision process approach","volume":"60","author":"Magni","year":"2000","journal-title":"Int J Med Inf"},{"issue":"9","key":"10.1016\/j.vaccine.2018.06.059_b0110","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-qaly threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"New Engl J Med"},{"issue":"17","key":"10.1016\/j.vaccine.2018.06.059_b0115","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1016\/j.vaccine.2011.09.079","article-title":"Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice?","volume":"30","author":"Bilcke","year":"2012","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2018.06.059_b0120","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/archinte.1995.00430150071008","article-title":"The incidence of herpes zoster","volume":"155","author":"Donahue","year":"1995","journal-title":"Arch Internal Med"},{"issue":"8","key":"10.1016\/j.vaccine.2018.06.059_b0125","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1525-1497.2005.0150.x","article-title":"The incidence of herpes zoster in a united states administrative database","volume":"20","author":"Insinga","year":"2005","journal-title":"J Gen Internal Med"},{"issue":"3","key":"10.1016\/j.vaccine.2018.06.059_b0130","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/cid\/ciq077","article-title":"Herpes zoster incidence among insured persons in the united states, 1993\u20132006: evaluation of impact of varicella vaccination","volume":"52","author":"Leung","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2018.06.059_b0135","doi-asserted-by":"crossref","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.vaccine.2018.06.059_b0140","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/1471-2334-11-302","article-title":"Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain","volume":"11","author":"Cebri\u00e1n-Cuenca","year":"2011","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2018.06.059_b0145","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/1471-2334-10-230","article-title":"Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study","volume":"10","author":"Gialloreti","year":"2010","journal-title":"BMC Infect Dis"},{"issue":"01","key":"10.1016\/j.vaccine.2018.06.059_b0150","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S0950268808000678","article-title":"Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom","volume":"137","author":"Gauthier","year":"2009","journal-title":"Epidemiol Infect"},{"issue":"7264","key":"10.1016\/j.vaccine.2018.06.059_b0155","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1136\/bmj.321.7264.794","article-title":"Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up","volume":"321","author":"Helgason","year":"2000","journal-title":"BMJ"},{"issue":"157","key":"10.1016\/j.vaccine.2018.06.059_b0160","first-page":"571","article-title":"Postherpetic neuralgia","volume":"25","author":"Hope-Simpson","year":"1975","journal-title":"Brit J Gen Pract"},{"issue":"4","key":"10.1016\/j.vaccine.2018.06.059_b0165","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.vaccine.2008.11.012","article-title":"Herpes zoster burden of illness and health care resource utilisation in the australian population aged 50 years and older","volume":"27","author":"Stein","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.059_b0170","first-page":"1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"vol. 82","author":"Yawn","year":"2007"},{"issue":"8","key":"10.1016\/j.vaccine.2018.06.059_b0175","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/AJP.0b013e3181eef686","article-title":"A prospective study of the herpes zoster severity of illness","volume":"26","author":"Drolet","year":"2010","journal-title":"Clin J Pain"},{"issue":"22","key":"10.1016\/j.vaccine.2018.06.059_b0180","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2018.06.059_b0185","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1331\/JAPhA.2014.13140","article-title":"Economic analysis of a herpes zoster vaccination program in 19 affiliated supermarket pharmacies","volume":"54","author":"Hedden","year":"2014","journal-title":"J Am Pharm Assoc: JAPhA"},{"issue":"1","key":"10.1016\/j.vaccine.2018.06.059_b0190","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1331\/JAPhA.2009.08030","article-title":"Retrospective financial analysis of a herpes zoster vaccination program from an independent community pharmacy perspective","volume":"49","author":"Wood","year":"2008","journal-title":"J Am Pharm Assoc: JAPhA"},{"issue":"2","key":"10.1016\/j.vaccine.2018.06.059_b0195","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1331\/JAPhA.2012.11207","article-title":"Three-year financial analysis of pharmacy services at an independent community pharmacy","volume":"52","author":"Doucette","year":"2012","journal-title":"J Am Pharm Assoc"},{"issue":"1","key":"10.1016\/j.vaccine.2018.06.059_b0200","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.amjmed.2013.09.013","article-title":"Anaphylaxis: a payor\u2019s perspective on epinephrine autoinjectors","volume":"127","author":"Dunn","year":"2014","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2018.06.059_b0205","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1365-2796.2011.02474.x","article-title":"Safety of zoster vaccine in adults from a large managed-care cohort: a vaccine safety datalink study","volume":"271","author":"Tseng","year":"2012","journal-title":"J Internal Med"},{"issue":"12","key":"10.1016\/j.vaccine.2018.06.059_b0210","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.vaccine.2012.01.045","article-title":"Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study","volume":"30","author":"Drolet","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.06.059_b0215","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3111\/13696998.2010.502854","article-title":"Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in belgium","volume":"13","author":"Annemans","year":"2010","journal-title":"J Med Econ"},{"issue":"5","key":"10.1016\/j.vaccine.2018.06.059_b0220","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3111\/13696998.2011.607482","article-title":"Work and productivity loss related to herpes zoster","volume":"14","author":"Singhal","year":"2011","journal-title":"J Med Econ"},{"issue":"3","key":"10.1016\/j.vaccine.2018.06.059_b0225","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00019053-200826030-00006","article-title":"Community and patient values for preventing herpes zoster","volume":"26","author":"Lieu","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.vaccine.2018.06.059_b0230","doi-asserted-by":"crossref","first-page":"113","DOI":"10.7326\/0003-4819-139-2-200307150-00011","article-title":"Diagnosis and management of adults with pharyngitis: a cost-effectiveness analysis","volume":"139","author":"Neuner","year":"2003","journal-title":"Ann Internal Med"},{"key":"10.1016\/j.vaccine.2018.06.059_b0235","unstructured":"Arias Elizabeth. United States life tables, 2010; 2010."},{"issue":"1","key":"10.1016\/j.vaccine.2018.06.059_b0240","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jpain.2007.10.002","article-title":"Natural history and treatment of herpes zoster","volume":"9","author":"Schmader","year":"2008","journal-title":"J Pain"},{"issue":"1","key":"10.1016\/j.vaccine.2018.06.059_b0245","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/infdis\/jiv480","article-title":"Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults","volume":"213","author":"Levin","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.06.059_b0250","doi-asserted-by":"crossref","unstructured":"Gilbert Peter B, Gabriel Erin E, Miao Xiaopeng, Li Xiaoming, Su Shu-Chih, Parrino Janie, et al. Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. J Infect Dis 2014;jiu279.","DOI":"10.1093\/infdis\/jiu279"},{"key":"10.1016\/j.vaccine.2018.06.059_b0255","unstructured":"Zhang Y, Haipeng W, Denton BT, Wilson JR, Lobo JM. Conducting probabilistic sensitivity analysis for decision models based on markov chains; 2015. https:\/\/pdfs.semanticscholar.org\/2d0e\/915673707c30f2be8365adf4974492e6fdad.pdf."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18309009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18309009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:28:36Z","timestamp":1759400916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18309009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":51,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0264410X18309009"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.06.059","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determining the optimal strategy for the live-attenuated herpes zoster vaccine in adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.06.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}